Vonicog alfa: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 23: | Line 23: | ||
[[Category:Biotechnology]] | [[Category:Biotechnology]] | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
Revision as of 06:22, 11 February 2025
Vonicog alfa is a recombinant form of human coagulation factor XIII A-subunit. It is produced by recombinant DNA technology in a human cell line. Vonicog alfa is used for the routine prophylactic treatment of congenital factor XIII A-subunit deficiency.
Etymology
The name "Vonicog alfa" is derived from the words "von Willebrand factor" and "coagulation factor". The suffix "alfa" indicates that it is a recombinant form of the protein.
Medical Uses
Vonicog alfa is used for the routine prophylactic treatment of congenital factor XIII A-subunit deficiency. This is a rare and potentially life-threatening disorder that is characterized by abnormal blood clotting that can result in abnormal bleeding. Vonicog alfa works by replacing the missing coagulation factor XIII A-subunit in patients with this disorder.
Pharmacology
Vonicog alfa is a recombinant form of human coagulation factor XIII A-subunit. It is produced by recombinant DNA technology in a human cell line. The protein is secreted into the cell culture medium, purified, and formulated into a sterile solution for intravenous injection.
Side Effects
The most common side effects of vonicog alfa include headache, pain in the extremities, and injection site reactions. Less common side effects include allergic reactions, which can be serious and require immediate medical attention.
